Rilvegostomig (Anti-PD-1 & TIGIT) PD-1/PD-L1 inhibitor | Read Reviews & Product Use Citations

Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung cancer (NSCLC). MW: 146.06.

Quality Control

Cited in Nature Medicine for its top-tier quality
SDS
Datasheet

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Specificity

Name	Citation	PD-1/PD-L1 interaction	PD-1	PD-L1	PD-1/PD-L1	Others
GS-4224	0	++++			++++
INCB086550	1	++			++
BMS-1001	0	+			+
BMS-1166	8	+++
PD-1/PD-L1 Inhibitor 3	13	+++
BMS-1	13	++
BMS202	26	+
CA-170 (AUPM-170)	0			✔
SR 0987	1		✔			IL17,RORγt
Spartalizumab (anti-PD-1)	3		✔
Camrelizumab (anti-PD-1)	2		✔
AUNP-12	3			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung cancer (NSCLC). MW: 146.06.

Description

Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung cancer (NSCLC). MW: 146.06.

Product Details

CAS No.	N/A
Source	CHO
Storage (From the date of receipt)	-80℃(avoid freeze-thaw cycles)

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.